

ASX Release
13th February 2019

Federal Court approves in principle settlement between Cryosite and the ACCC

On 8 February 2019 Cryosite Limited (**Cryosite**) (ASX: CTE) announced that it had reached an in principle settlement with the Australian Competition and Consumer Commission (**ACCC**) in relation to the proceeding against Cryosite in the Federal Court of Australia. As stated in that announcement, the settlement remained subject to approval by the Federal Court.

The Federal Court of Australia has today approved the in principle settlement between the ACCC and Cryosite. The Federal Court of Australia made orders in the proposed terms sought by the ACCC and Cryosite, as announced by Cryosite on 8 February 2019.

Now that this matter has been resolved Cryosite can apply its full focus to its growing clinical trial logistic business supported by existing long-term Cord Blood and Tissue storage contracts.

Bryan Dulhunty
Chairman